Home/Active Biotech/Hans Kolam
HK

Hans Kolam

Chief Financial Officer

Active Biotech

Therapeutic Areas

Active Biotech Pipeline

DrugIndicationPhase
TasquinimodMyelofibrosisPhase Ib/IIa
Laquinimod (eye drops)Inflammatory Eye Diseases (e.g., Uveitis)Phase I
NaptumomabSolid Tumors (combo with durvalumab)Phase Ib/II